Veterinary Biologics Market - Global Forecast To 2030
商品番号 : SMB-89683
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年10月 |
| ページ数 | 317 |
| 図表数 | 373 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
動物用生物学的製剤市場 – 製品（モノクローナル抗体、診断キット、免疫グロブリンおよび抗毒素）、用途（注射剤、経口剤）、用途（感染症予防、皮膚科、疼痛管理）、動物、エンドユーザー – 2030年までの世界予測
世界の動物用生物学的製剤市場は、予測期間中に5.2%のCAGRで成長し、2025年の27億2,000万米ドルから2030年には35億1,000万米ドルに達すると予測されています。
動物用生物学的製剤市場は、コンパニオンアニマル人口の増加とペット飼育数の増加に牽引され、大幅な成長を遂げています。慢性疾患への懸念の高まりは、獣医治療の需要をさらに押し上げています。政府や動物福祉団体は、ペットと家畜の両方において、皮膚疾患の早期診断と治療を促す啓発キャンペーンを積極的に展開しています。さらに、ペット保険の普及と動物医療費の高騰は、専門的な獣医サービスへのアクセスを向上させ、市場拡大を後押ししています。しかしながら、市場はペットケア費用の高騰といった課題に直面しており、治療の普及を阻む可能性があります。さらに、厳格な規制ガイドラインと長期にわたる医薬品承認プロセスも、市場の成長を抑制しています。
本レポートは、動物の種類、投与経路、製品、用途、エンドユーザー、地域に基づいて、動物用生物製剤市場を分析しています。また、市場の成長に影響を与える推進要因、制約要因、機会、課題といった要因についても分析しています。市場における機会と課題を分析し、市場リーダーの競争環境に関する詳細な情報を提供しています。さらに、ミクロ市場を個々の成長傾向の観点から分析し、5つの主要地域とそれぞれの国における市場セグメントの収益を予測しています。
本レポートは、既存企業だけでなく新規参入企業や小規模企業にとっても、市場の動向を把握し、シェア拡大に繋げる上で役立ちます。本レポートをご購入いただいた企業は、以下の5つの戦略のいずれか、または組み合わせて活用することができます。
本レポートでは、以下の点について洞察を提供します。
- 主要な推進要因（コンパニオンアニマルの人口とペット飼育数の急増、人獣共通感染症の発生率の増加、感染症を標的とするモノクローナル抗体の革新、政府機関および動物保健団体による支援策、動物由来食品の需要増加）、制約要因（獣医診断検査の高コスト、規制上のハードルと長期にわたる承認期間）、機会（戦略的提携・パートナーシップの進展、新興市場における未開拓の成長ポテンシャル）、課題（低所得国における獣医師の認知度不足と訓練を受けた獣医師の不足）の分析。
- 製品開発／イノベーション：動物用生物学的製剤市場における今後の技術、研究開発活動、製品投入に関する詳細な洞察。
- 市場開発：収益性の高い新興市場に関する包括的な情報。本レポートでは、様々な種類のバイオ医薬品の市場を地域ごとに分析しています。
- 市場多様化：動物用バイオ医薬品市場における製品、未開拓地域、最近の動向、投資に関する包括的な情報。
- 競合評価：動物用バイオ医薬品市場における主要企業の市場シェア、戦略、製品、流通ネットワーク、製造能力に関する詳細な評価。
Report Description
The global veterinary biologics market is projected to reach USD 3.51 billion by 2030 from USD 2.72 billion in 2025, at a CAGR of 5.2% during the forecast period.
The veterinary biologics market is experiencing significant growth, driven by an expanding companion animal population and rising pet ownership. Increasing concerns about chronic diseases have further boosted demand for veterinary treatments. Government and animal welfare organizations actively promote awareness campaigns, encouraging early diagnosis and treatment of dermatological conditions in both pets and farm animals. Additionally, the growing adoption of pet insurance and high expenditure on animal healthcare support market expansion by improving access to specialized veterinary services. However, the market faces challenges such as the rising cost of pet care, which can limit treatment adoption. Moreover, strict regulatory guidelines and lengthy drug approval processes further restrain market growth.
“The monoclonal antibodies segment has accounted for the largest market share in the veterinary biologics market.”
Monoclonal antibodies are projected to experience rapid growth in the veterinary biologics market, driven by their targeted action, high effectiveness, and increasing adoption in livestock health management. These biologics are increasingly used to prevent and treat specific diseases by precisely targeting pathogens or toxins, providing a more selective and effective alternative to traditional therapies like antibiotics. In livestock applications, monoclonal antibodies are especially valuable for conditions that require swift immune support, resulting in decreased morbidity and higher productivity. Their use aligns with the global shift toward sustainable animal farming practices and the reduction of antimicrobial resistance (AMR), making them a preferred choice for advanced biologic treatments.
“The dermatology segment accounted for the largest market share in 2024 in the veterinary biologics market.”
The dermatology segment is expected to dominate the veterinary biologics market because of the high prevalence of skin disorders like atopic dermatitis, mange, and flea- or tick-borne skin infections in companion animals. Increasing pet ownership and greater awareness of animal health have boosted demand for advanced dermatological treatments. Biologics, such as monoclonal antibodies, are becoming more popular as effective, targeted therapies with fewer side effects compared to traditional drugs. More approvals of dermatology-focused veterinary biologics, including those targeting chronic skin allergies, further strengthen this segment. Additionally, dermatological issues are among the most common reasons for veterinary visits, ensuring steady demand. Growth in companion animal insurance coverage is also supporting the adoption of high-cost biologics. Overall, these factors position dermatology as the leading segment in the veterinary biologics market.
“North America has accounted for the largest market share in 2024.”
North America held the largest market share in 2024, supported by a well-established veterinary healthcare infrastructure and high pet ownership rates. The region has a strong presence of leading market players investing in research and development for innovative monoclonal antibody therapies. Rising awareness about pet health, along with increasing spending on veterinary care, drives market growth. Additionally, the growing demand for premium pet care products further contributes to North America’s dominance in the global veterinary monoclonal antibody industry.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–75%, Tier 2–15%, and Tier 3– 10%
- By Designation: C-level–30%, Director-level–23%, and Other Designations–47%
- By Region: North America–35%, Europe–20%, Asia Pacific–25%, Latin America–13%, and Middle East & Africa–7%
The major players operating in the veterinary biologics market are Zoetis (US), Elanco (US), and Merck & Co., Inc. (US).
Research Coverage
This report studies the veterinary biologics market based on animal type, route of administration, product, application, end user, and region. The report also examines factors such as drivers, restraints, opportunities, and challenges that affect market growth. It analyzes the opportunities and challenges within the market and provides details about the competitive landscape for market leaders. Additionally, the report analyzes micro markets in terms of their individual growth trends and forecasts the revenue of market segments across five main regions and their respective countries.
Reasons to Buy the Report
The report can help established firms, as well as new entrants/smaller firms, gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the five strategies mentioned below.
This report provides insights into the following points:
- Analysis of key drivers (Surge in companion animal population and pet ownership. Increasing incidence of infectious zoonotic diseases, Innovations in monoclonal antibodies targeting infectious diseases, Supportive initiatives by government agencies and animal health organization, Growing demand for animal-derived food products), restraints (High cost of veterinary diagnostic tests, Regulatory hurdles and long approval timelines), opportunities (evolving landscape of strategic collaborations and partnerships, untapped growth potential in emerging markets, challenges (Limited Awareness and Shortage of Trained Veterinarians in Low-Income Countries.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the veterinary biologics market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of biologic treatments across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the veterinary biologics market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the veterinary biologics market.
Table of Contents
1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.3 STUDY SCOPE 30
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 30
1.3.2 INCLUSIONS & EXCLUSIONS 31
1.3.3 YEARS CONSIDERED 32
1.3.4 CURRENCY CONSIDERED 32
1.4 STAKEHOLDERS 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.1.1 SECONDARY DATA 34
2.1.1.1 Key secondary sources 34
2.1.1.2 Key data from secondary sources 35
2.1.2 PRIMARY DATA 35
2.1.2.1 Primary sources 36
2.1.2.2 Key objectives of primary research 36
2.1.2.3 Key industry insights 37
2.1.2.4 Breakdown of primaries 37
2.2 MARKET SIZE ESTIMATION 39
2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH) 39
2.2.2 EPIDEMIOLOGY-BASED APPROACH 40
2.2.3 COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS 41
2.2.4 TOP-DOWN APPROACH 41
2.2.5 BOTTOM-UP APPROACH 42
2.3 MARKET GROWTH RATE PROJECTION 42
2.4 DATA TRIANGULATION 44
2.5 STUDY ASSUMPTIONS 45
2.6 RESEARCH LIMITATIONS 45
2.7 RISK ANALYSIS 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 52
4.1 VETERINARY BIOLOGICS MARKET OVERVIEW 52
4.2 NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE AND COUNTRY 53
4.3 VETERINARY BIOLOGICS MARKET SHARE, BY PRODUCT TYPE, 2025 VS. 2030 53
4.4 VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2025 VS. 2030 (USD MILLION) 54
4.5 VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION) 54
4.6 VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 55
4.7 VETERINARY BIOLOGICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
5.2.1 DRIVERS 58
5.2.1.1 Surge in companion animal population and pet ownership 58
5.2.1.2 Increasing incidence of infectious zoonotic diseases 59
5.2.1.3 Innovations in monoclonal antibodies targeting infectious diseases 60
5.2.1.4 Supportive initiatives by government agencies and animal health organizations 61
5.2.1.5 Rising demand for animal-derived food products 61
5.2.2 RESTRAINTS 63
5.2.2.1 High cost of veterinary diagnostic tests 63
5.2.2.2 Regulatory hurdles and long approval timelines 64
5.2.2.3 Rising pet care costs 64
5.2.3 OPPORTUNITIES 65
5.2.3.1 Evolving landscape of strategic collaborations and acquisitions 65
5.2.3.2 Untapped growth potential in emerging economies 66
5.2.4 CHALLENGES 66
5.2.4.1 Limited awareness and shortage of trained veterinarians in low-income countries 66
5.2.4.2 Stringent regulatory requirements for licensing veterinary biologics 67
5.3 TECHNOLOGY ANALYSIS 67
5.3.1 KEY TECHNOLOGIES 67
5.3.1.1 Hybridoma technology 67
5.3.1.2 Biosensor-based diagnostic systems 68
5.3.2 COMPLEMENTARY TECHNOLOGIES 68
5.3.2.1 Long-acting injectables 68
5.3.2.2 Next-generation sequencing 68
5.3.3 ADJACENT TECHNOLOGIES 69
5.3.3.1 Wearable biosensors & remote monitoring devices 69
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 69
5.5 VALUE CHAIN ANALYSIS 70
5.6 TRADE ANALYSIS 71
5.6.1 IMPORT DATA FOR HS CODE 300214, 2021–2024 72
5.6.2 EXPORT DATA FOR HS CODE 300214, 2021–2024 72
5.7 PORTER’S FIVE FORCES ANALYSIS 73
5.7.1 THREAT OF NEW ENTRANTS 74
5.7.2 THREAT OF SUBSTITUTES 74
5.7.3 BARGAINING POWER OF SUPPLIERS 74
5.7.4 BARGAINING POWER OF BUYERS 74
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 75
5.8 KEY STAKEHOLDERS & BUYING CRITERIA 75
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS 75
5.8.2 KEY BUYING CRITERIA 76
5.9 REGULATORY ANALYSIS 77
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
5.9.2 REGULATORY FRAMEWORK 80
5.9.2.1 North America 80
5.9.2.2 Europe 81
5.9.2.3 Asia Pacific 81
5.9.2.4 Latin America 81
5.9.2.5 Middle East & Africa 81
5.10 PATENT ANALYSIS 82
5.10.1 PATENT PUBLICATION TREND 82
5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS 83
5.10.3 INNOVATIONS AND PATENT REGISTRATIONS 83
5.11 PRICING ANALYSIS 84
5.11.1 INDICATIVE PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY KEY PLAYER, 2024 84
5.11.2 INDICATIVE PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY REGION, 2022–2024 85
5.12 KEY CONFERENCES & EVENTS, 2025–2026 86
5.13 ECOSYSTEM ANALYSIS 87
5.13.1 ROLE IN ECOSYSTEM 88
5.14 REIMBURSEMENT ANALYSIS 88
5.15 UNMET NEEDS 89
5.16 IMPACT OF AI/GEN AI ON VETERINARY BIOLOGICS MARKET 90
5.16.1 POTENTIAL OF AI IN VETERINARY BIOLOGICS 90
5.16.2 AI USE CASES 90
5.16.3 KEY COMPANIES IMPLEMENTING AI 91
5.17 INVESTMENT & FUNDING SCENARIO 92
5.18 PIPELINE ANALYSIS 92
5.19 IMPACT OF 2025 US TARIFF ON VETERINARY BIOLOGICS MARKET 94
5.19.1 INTRODUCTION 94
5.19.2 KEY TARIFF RATES 95
5.19.3 PRICE IMPACT ANALYSIS 95
5.19.4 IMPACT ON COUNTRY/REGION 96
5.19.5 IMPACT ON END-USE INDUSTRIES 96
5.19.5.1 Veterinary hospitals & clinics 96
5.19.5.2 Veterinary diagnostic labs 96
5.19.5.3 Other end users 96
6 VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE 97
6.1 INTRODUCTION 98
6.2 MONOCLONAL ANTIBODIES 98
6.2.1 INCREASED PET OWNERSHIP AND HUMANIZATION TO RAISE HEALTH AWARENESS AND SPENDING ON ANTIBODY THERAPIES 98
6.3 IMMUNOGLOBULINS & ANTITOXINS 100
6.3.1 INCREASED PREVALENCE OF ZOONOTIC AND TOXIN-MEDIATED DISEASES TO FUEL MARKET GROWTH 100
6.4 IMMUNOMODULATORS & IMMUNOSTIMULANTS 102
6.4.1 IMMUNOMODULATORS & IMMUNOSTIMULANTS TO CORRECT IMMUNE DYSFUNCTIONS AND CONTROL OVERACTIVE IMMUNE CONDITIONS 102
6.5 DIAGNOSTIC KITS 103
6.5.1 DIAGNOSTIC KITS TO IMPROVE DISEASE SURVEILLANCE AND MANAGEMENT IN COMPANION ANIMALS, LIVESTOCK, AND POULTRY 103
7 VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE 106
7.1 INTRODUCTION 107
7.2 COMPANION ANIMALS 107
7.2.1 CANINE 109
7.2.1.1 Widespread ownership of pet dogs to generate consistent demand for preventive care and advanced biologics 109
7.2.2 FELINE 111
7.2.2.1 Rising pet cat population and increasing feline diseases to propel market growth 111
7.3 LIVESTOCK ANIMALS 113
7.3.1 BOVINE 115
7.3.1.1 Need for better herd healthcare and introduction of antibody-based biologics to fuel segment growth 115
7.3.2 SMALL RUMINANT 117
7.3.2.1 Increasing global demand for sheep & goat meat and expanding herd size to boost market growth 117
7.3.3 PORCINE 119
7.3.3.1 Innovation in monoclonal antibodies for infectious diseases to drive market 119
7.3.4 POULTRY 121
7.3.4.1 Rising frequency of poultry diseases to augment market growth for better poultry health and improved food security 121
7.3.5 EQUINE 123
7.3.5.1 Equestrian sports, recreational riding, and managing failure of passive transfer (FPT) in foals to drive market 123
8 VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION 125
8.1 INTRODUCTION 126
8.2 INJECTABLE ROUTE OF ADMINISTRATION 126
8.2.1 SUBCUTANEOUS ROUTE OF ADMINISTRATION 128
8.2.1.1 Ease of administration, reduced pain, and lower risk of tissue damage to aid market growth 128
8.2.2 INTRAMUSCULAR ROUTE OF ADMINISTRATION 130
8.2.2.1 Better immune response and lower rate of injection-site reactions to fuel market growth 130
8.2.3 INTRAVENOUS ROUTE OF ADMINISTRATION 131
8.2.3.1 Rapid action and targeted therapy to drive adoption of intravenous biologics 131
8.2.4 OTHER INJECTABLE ROUTES OF ADMINISTRATION 133
8.3 ORAL ROUTE OF ADMINISTRATION 134
8.3.1 EASE OF ADMINISTRATION AND COST-EFFECTIVENESS TO FOCUS ON LARGE-SCALE, NON-INVASIVE ORAL DELIVERY 134
8.4 OTHER ROUTES OF ADMINISTRATION 136
9 VETERINARY BIOLOGICS MARKET, BY APPLICATION 138
9.1 INTRODUCTION 139
9.2 DERMATOLOGY 139
9.2.1 PREVALENCE OF CHRONIC SKIN CONDITIONS TO AUGMENT VETERINARY DERMATOLOGY MARKET GROWTH 139
9.3 DIAGNOSTIC TESTING 141
9.3.1 RISING PREVALENCE OF ZOONOTIC AND VIRAL DISEASES TO INCREASE DEMAND FOR BIOLOGIC-BASED DIAGNOSTIC TOOLS 141
9.4 PAIN MANAGEMENT 142
9.4.1 NEED FOR NON-OPIOID, SIDE-EFFECT-FREE PAIN SOLUTIONS AMONG PET OWNERS TO DRIVE MARKET 142
9.5 INFECTIOUS DISEASE PREVENTION 144
9.5.1 RISING INCIDENCE OF ZOONOTIC DISEASES AND ACUTE INFECTIONS TO ACCELERATE USE OF VETERINARY BIOLOGICS 144
9.6 ONCOLOGY 145
9.6.1 FOCUS ON IMMUNE-TARGETED CONTROL OF AGGRESSIVE CANCEROUS TUMORS TO AID MARKET GROWTH 145
9.7 OTHER APPLICATIONS 146
10 VETERINARY BIOLOGICS MARKET, BY END USER 148
10.1 INTRODUCTION 149
10.2 VETERINARY HOSPITALS & CLINICS 149
10.2.1 INCREASE IN VETERINARY SPECIALISTS AND RISE IN PET OWNERSHIP TO PROPEL MARKET GROWTH 149
10.3 VETERINARY DIAGNOSTIC LABS 150
10.3.1 VETERINARY DIAGNOSTIC LABS TO BECOME ESSENTIAL IN DISEASE DETECTION WITH PREVENTIVE BIOLOGIC INTERVENTIONS 150
10.4 OTHER END USERS 152
11 VETERINARY BIOLOGICS MARKET, BY REGION 154
11.1 INTRODUCTION 155
11.2 NORTH AMERICA 156
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 156
11.2.2 US 159
11.2.2.1 US to dominate North American veterinary biologics market during forecast period 159
11.2.3 CANADA 162
11.2.3.1 Ongoing developments in veterinary monoclonal antibodies and increasing animal health expenditure to fuel market growth 162
11.3 EUROPE 165
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 165
11.3.2 GERMANY 168
11.3.2.1 Established veterinary infrastructure and innovation funding to provide favorable environment for biologics adoption 168
11.3.3 UK 170
11.3.3.1 Strong regulatory framework and high pet population to boost market growth 170
11.3.4 FRANCE 173
11.3.4.1 Increase in companion animal health spending by pet owners to propel market growth 173
11.3.5 ITALY 175
11.3.5.1 Better availability of pet products through large-scale outlets to augment market growth 175
11.3.6 SPAIN 178
11.3.6.1 Increased pet population and favorable government regulations to drive market 178
11.3.7 NETHERLANDS 180
11.3.7.1 Focus on meat export to positively influence veterinary biologics market 180
11.3.8 REST OF EUROPE 182
11.4 ASIA PACIFIC 184
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 185
11.4.2 JAPAN 187
11.4.2.1 Growing consumption of animal-derived products to propel market growth 187
11.4.3 CHINA 190
11.4.3.1 Large pool of food-producing animals and high companion animal ownership to propel market growth 190
11.4.4 INDIA 193
11.4.4.1 Rising demand for dairy products to fuel market growth 193
11.4.5 AUSTRALIA 196
11.4.5.1 Rise in pet ownership to support increased spending on veterinary care 196
11.4.6 SOUTH KOREA 198
11.4.6.1 Expanding pet care industry and increasing chronic veterinary diseases to drive market 198
11.4.7 NEW ZEALAND 201
11.4.7.1 Increased pet ownership and demand for advanced veterinary treatments to drive market 201
11.4.8 REST OF ASIA PACIFIC 203
11.5 LATIN AMERICA 205
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 206
11.5.2 BRAZIL 208
11.5.2.1 Large-scale livestock operations and strong veterinary infrastructure to drive market 208
11.5.3 MEXICO 211
11.5.3.1 Increasing demand for targeted biologics in livestock and pets to drive market growth 211
11.5.4 REST OF LATIN AMERICA 213
11.6 MIDDLE EAST & AFRICA 215
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 215
11.6.2 GCC COUNTRIES 218
11.6.2.1 Kingdom of Saudi Arabia (KSA) 220
11.6.2.1.1 Technology advancements in veterinary diagnostics to boost demand 220
11.6.2.2 United Arab Emirates (UAE) 223
11.6.2.2.1 Favorable government support to drive market 223
11.6.2.3 Rest of GCC Countries 225
11.6.3 REST OF MIDDLE EAST & AFRICA 227
12 COMPETITIVE LANDSCAPE 230
12.1 INTRODUCTION 230
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 230
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY BIOLOGICS MARKET 230
12.3 REVENUE ANALYSIS, 2022–2024 231
12.4 MARKET SHARE ANALYSIS, 2024 232
12.4.1 VETERINARY BIOLOGICS MARKET SHARE ANALYSIS 232
12.4.2 US: VETERINARY BIOLOGICS MARKET SHARE ANALYSIS, 2024 233
12.4.3 VETERINARY DIAGNOSTICS KITS MARKET SHARE ANALYSIS 235
12.4.4 US: VETERINARY DIAGNOSTIC KITS MARKET SHARE ANALYSIS, 2024 236
12.5 RANKING OF KEY PLAYERS 238
12.5.1 VETERINARY BIOLOGICS MARKET RANKING 238
12.5.2 VETERINARY DIAGNOSTIC KITS MARKET RANKING 239
12.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 239
12.6.1 STARS 239
12.6.2 EMERGING LEADERS 239
12.6.3 PERVASIVE PLAYERS 239
12.6.4 PARTICIPANTS 239
12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 241
12.6.5.1 Company footprint 241
12.6.5.2 Region footprint 242
12.6.5.3 Product type footprint 243
12.6.5.4 Animal type footprint 244
12.6.5.5 Application footprint 245
12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 246
12.7.1 PROGRESSIVE COMPANIES 246
12.7.2 RESPONSIVE COMPANIES 246
12.7.3 DYNAMIC COMPANIES 246
12.7.4 STARTING BLOCKS 246
12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 248
12.7.5.1 Detailed list of key startup/SMEs 248
12.7.5.2 Competitive benchmarking of key startups/SMEs 249
12.8 BRAND/PRODUCT COMPARISON 250
12.9 COMPANY VALUATION & FINANCIAL METRICS 251
12.9.1 FINANCIAL METRICS 251
12.9.2 COMPANY VALUATION 251
12.10 COMPETITIVE SCENARIO 252
12.10.1 PRODUCT LAUNCHES & APPROVALS 252
12.10.2 DEALS 253
12.10.3 EXPANSIONS 254
12.10.4 OTHER DEVELOPMENTS 255
13 COMPANY PROFILES 256
13.1 KEY PLAYERS 256
13.1.1 ZOETIS SERVICES LLC 256
13.1.1.1 Business overview 256
13.1.1.2 Products offered 257
13.1.1.3 Recent developments 259
13.1.1.3.1 Product launches & approvals 259
13.1.1.3.2 Deals 260
13.1.1.3.3 Expansions 260
13.1.1.3.4 Other developments 261
13.1.1.4 MnM view 261
13.1.1.4.1 Right to win 261
13.1.1.4.2 Strategic choices 261
13.1.1.4.3 Weaknesses & competitive threats 261
13.1.2 IDEXX 262
13.1.2.1 Business overview 262
13.1.2.2 Products offered 263
13.1.2.3 Recent developments 267
13.1.2.3.1 Product launches 267
13.1.2.4 MnM view 267
13.1.2.4.1 Right to win 267
13.1.2.4.2 Strategic choices 268
13.1.2.4.3 Weaknesses & competitive threats 268
13.1.3 ELANCO 269
13.1.3.1 Business overview 269
13.1.3.2 Products offered 270
13.1.3.3 Recent developments 271
13.1.3.3.1 Product launches 271
13.1.3.3.2 Deals 271
13.1.3.3.3 Expansions 272
13.1.3.4 MnM view 272
13.1.3.4.1 Right to win 272
13.1.3.4.2 Strategic choices 272
13.1.3.4.3 Weaknesses & competitive threats 272
13.1.4 MERCK & CO., INC. 273
13.1.4.1 Business overview 273
13.1.4.2 Products offered 274
13.1.4.3 Recent developments 275
13.1.4.3.1 Product launches 275
13.1.4.3.2 Expansions 275
13.1.4.4 MnM view 275
13.1.4.4.1 Right to win 275
13.1.4.4.2 Strategic choices 276
13.1.4.4.3 Weaknesses & competitive threats 276
13.1.5 THERMO FISHER SCIENTIFIC INC. 277
13.1.5.1 Business overview 277
13.1.5.2 Products offered 278
13.1.5.3 MnM view 279
13.1.5.3.1 Right to win 279
13.1.5.3.2 Strategic choices 279
13.1.5.3.3 Weaknesses & competitive threats 279
13.1.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 280
13.1.6.1 Business overview 280
13.1.6.2 Products offered 281
13.1.6.3 Recent developments 282
13.1.6.3.1 Deals 282
13.1.6.3.2 Expansions 282
13.1.7 NEOGEN CORPORATION 283
13.1.7.1 Business overview 283
13.1.7.2 Products offered 284
13.1.7.3 Recent developments 285
13.1.7.3.1 Deals 285
13.1.8 BIO-RAD LABORATORIES, INC. 286
13.1.8.1 Business overview 286
13.1.8.2 Products offered 287
13.1.9 IMMUCELL CORPORATION 288
13.1.9.1 Business overview 288
13.1.9.2 Products offered 289
13.1.9.3 Recent developments 290
13.1.9.3.1 Other developments 290
13.1.10 INNOVATIVE DIAGNOSTICS 291
13.1.10.1 Business overview 291
13.1.10.2 Products offered 291
13.2 OTHER PLAYERS 295
13.2.1 BIONOTE USA INC. 295
13.2.2 BIOCHEK 296
13.2.3 PLASVACC USA 297
13.2.4 NOVAVIVE INC. 298
13.2.5 MG BIOLOGICS 299
13.2.6 STALLERGENES GREER 300
13.2.7 BIOSTONE ANIMAL HEALTH 301
13.2.8 COLORADO SERUM COMPANY 302
13.2.9 PADULA SERUMS PTY LTD. 303
13.2.10 LAKE IMMUNOGENICS 304
13.2.11 INBIOS INTERNATIONAL, INC. 304
13.2.12 PRINCETON BIOMEDITECH CORPORATION 305
13.2.13 TETRACORE, INC. 306
13.2.14 VMRD, INC. 307
13.2.15 ANIMAB 308
14 APPENDIX 309
14.1 DISCUSSION GUIDE 309
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 312
14.3 AVAILABLE CUSTOMIZATIONS 314
14.3.1 GEOGRAPHIC ANALYSIS 314
14.3.2 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 314
14.3.3 COMPANY INFORMATION 314
14.3.4 PRODUCT ANALYSIS 314
14.3.5 COUNTRY-LEVEL VOLUME ANALYSIS 314
14.3.6 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 314
14.3.7 BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS) 314
14.4 RELATED REPORTS 315
14.5 AUTHOR DETAILS 316
LIST OF TABLES
TABLE 1 VETERINARY BIOLOGICS MARKET: INCLUSIONS & EXCLUSIONS 31
TABLE 2 VETERINARY BIOLOGICS MARKET: STUDY ASSUMPTIONS 45
TABLE 3 VETERINARY BIOLOGICS MARKET: RISK ANALYSIS 46
TABLE 4 PET (DOGS AND CATS) OWNERSHIP AND SPENDING IN US, 2024 58
TABLE 5 MAJOR OUTBREAKS OF ZOONOTIC DISEASES, 2022–2025 59
TABLE 6 PAST AND PROJECTED TRENDS IN MEAT AND MILK CONSUMPTION IN DEVELOPED COUNTRIES, 2002 VS. 2015 VS. 2030 VS. 2050 62
TABLE 7 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 62
TABLE 8 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS,
2020 VS. 2030 (THOUSAND METRIC TONS) 63
TABLE 9 IMPORT DATA FOR HS CODE 300214, BY COUNTRY,
2021–2024 (USD THOUSAND) 72
TABLE 10 EXPORT DATA FOR HS CODE 300214, BY COUNTRY,
2021–2024 (USD THOUSAND) 72
TABLE 11 VETERINARY BIOLOGICS MARKET: PORTER’S FIVE FORCES 73
TABLE 12 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF VETERINARY BIOLOGICS, BY END USER 76
TABLE 13 KEY BUYING CRITERIA FOR END USERS 77
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 77
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 17 VETERINARY BIOLOGICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS OF VETERINARY MONOCLONAL ANTIBODIES, 2023–2024 83
TABLE 18 INDICATIVE PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY KEY PLAYER, 2024 (USD) 84
TABLE 19 INDICATIVE SELLING PRICE OF VETERINARY MONOCLONAL ANTIBODIES,
BY REGION, 2022–2024 (USD) 85
TABLE 20 DETAILED LIST OF KEY CONFERENCES & EVENTS IN VETERINARY BIOLOGICS MARKET, JANUARY 2025–DECEMBER 2026 86
TABLE 21 VETERINARY BIOLOGICS MARKET: ROLE IN ECOSYSTEM 88
TABLE 22 UNMET NEEDS IN VETERINARY BIOLOGICS MARKET 89
TABLE 23 KEY COMPANIES IMPLEMENTING AI IN VETERINARY BIOLOGICS MARKET 91
TABLE 24 PIPELINE ANALYSIS IN VETERINARY BIOLOGICS MARKET 93
TABLE 25 US-ADJUSTED RECIPROCAL TARIFF RATES 95
TABLE 26 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR VETERINARY BIOLOGICS MARKET 95
TABLE 27 IMPACT OF US TARIFFS ON COUNTRIES/REGIONS 96
TABLE 28 VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 98
TABLE 29 LIST OF COMMERCIALLY AVAILABLE MONOCLONAL ANTIBODIES 99
TABLE 30 VETERINARY BIOLOGICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 99
TABLE 31 LIST OF USDA-APPROVED IMMUNOGLOBULINS & ANTITOXINS 100
TABLE 32 VETERINARY BIOLOGICS MARKET FOR IMMUNOGLOBULINS & ANTITOXINS,
BY COUNTRY, 2023–2030 (USD MILLION) 101
TABLE 33 VETERINARY BIOLOGICS MARKET FOR IMMUNOMODULATORS & IMMUNOSTIMULANTS, BY COUNTRY, 2023–2030 (USD MILLION) 102
TABLE 34 LIST OF LICENSED VETERINARY DIAGNOSTIC KITS AS APPROVED BY US FDA CENTER FOR VETERINARY BIOLOGICS 103
TABLE 35 VETERINARY BIOLOGICS MARKET FOR DIAGNOSTIC KITS, BY COUNTRY,
2023–2030 (USD MILLION) 105
TABLE 36 VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 107
TABLE 37 COMPANION ANIMALS OWNERSHIP IN US, 2024 107
TABLE 38 VETERINARY BIOLOGICS MARKET FOR COMPANION ANIMALS, BY TYPE,
2023–2030 (USD MILLION) 108
TABLE 39 VETERINARY BIOLOGICS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 40 KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR CANINES 110
TABLE 41 VETERINARY BIOLOGICS MARKET FOR CANINE, BY COUNTRY,
2023–2030 (USD MILLION) 110
TABLE 42 KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR FELINES 112
TABLE 43 VETERINARY BIOLOGICS MARKET FOR FELINE, BY COUNTRY,
2023–2030 (USD MILLION) 112
TABLE 44 VETERINARY BIOLOGICS MARKET FOR LIVESTOCK ANIMALS, BY TYPE,
2023–2030 (USD MILLION) 113
TABLE 45 VETERINARY BIOLOGICS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY,
2023–2030 (USD MILLION) 114
TABLE 46 KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR BOVINES 115
TABLE 47 VETERINARY BIOLOGICS MARKET FOR BOVINE, BY COUNTRY,
2023–2030 (USD MILLION) 116
TABLE 48 KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR SMALL RUMINANTS 117
TABLE 49 VETERINARY BIOLOGICS MARKET FOR SMALL RUMINANT, BY COUNTRY,
2023–2030 (USD MILLION) 118
TABLE 50 KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR PORCINES 119
TABLE 51 VETERINARY BIOLOGICS MARKET FOR PORCINE, BY COUNTRY,
2023–2030 (USD MILLION) 120
TABLE 52 KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR POULTRY 121
TABLE 53 VETERINARY BIOLOGICS MARKET FOR POULTRY, BY COUNTRY,
2023–2030 (USD MILLION) 122
TABLE 54 KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR EQUINES 123
TABLE 55 VETERINARY BIOLOGICS MARKET FOR EQUINE, BY COUNTRY,
2023–2030 (USD MILLION) 124
TABLE 56 VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 126
TABLE 57 VETERINARY BIOLOGICS MARKET FOR INJECTABLE ROUTE OF ADMINISTRATION, BY TYPE, 2023–2030 (USD MILLION) 127
TABLE 58 VETERINARY BIOLOGICS MARKET FOR INJECTABLE ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 59 VETERINARY BIOLOGICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 60 VETERINARY BIOLOGICS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 61 VETERINARY BIOLOGICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 62 VETERINARY BIOLOGICS MARKET FOR OTHER INJECTABLE ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 63 VETERINARY BIOLOGICS MARKET FOR ORAL ROUTE OF ADMINISTRATION,
BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 64 VETERINARY BIOLOGICS MARKET FOR OTHER ROUTES OF ADMINISTRATION,
BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 65 VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 139
TABLE 66 VETERINARY BIOLOGICS MARKET FOR DERMATOLOGY, BY COUNTRY,
2023–2030 (USD MILLION) 140
TABLE 67 VETERINARY BIOLOGICS MARKET FOR DIAGNOSTIC TESTNG, BY COUNTRY,
2023–2030 (USD MILLION) 141
TABLE 68 VETERINARY BIOLOGICS MARKET FOR PAIN MANAGEMENT, BY COUNTRY,
2023–2030 (USD MILLION) 143
TABLE 69 VETERINARY BIOLOGICS MARKET FOR INFECTIOUS DISEASE PREVENTION,
BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 70 VETERINARY BIOLOGICS MARKET FOR ONCOLOGY, BY COUNTRY,
2023–2030 (USD MILLION) 145
TABLE 71 VETERINARY BIOLOGICS MARKET FOR OTHER APPLICATIONS,BY COUNTRY,
2023–2030 (USD MILLION) 147
TABLE 72 VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION) 149
TABLE 73 AVERAGE TOTAL AMOUNT SPENT PER HOUSEHOLD ON PETS IN US,
2023–2024 (USD) 149
TABLE 74 VETERINARY BIOLOGICS MARKET FOR VETERINARY HOSPITALS & CLINICS,
BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 75 VETERINARY BIOLOGICS MARKET FOR VETERINARY DIAGNOSTIC LABS,
BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 76 VETERINARY BIOLOGICS MARKET FOR OTHER END USERS, BY COUNTRY,
2023–2030 (USD MILLION) 152
TABLE 77 VETERINARY BIOLOGICS MARKET, BY REGION, 2023–2030 (USD MILLION) 155
TABLE 78 VETERINARY BIOLOGICS MARKET FOR MONOCLONAL ANTIBODIES,
BY REGION, 2023–2030 (THOUSAND UNITS) 155
TABLE 79 NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY COUNTRY
2023–2030 (USD MILLION 157
TABLE 80 NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 158
TABLE 81 NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 158
TABLE 82 NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 158
TABLE 83 NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 159
TABLE 84 NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 159
TABLE 85 US: KEY MACROINDICATORS 160
TABLE 86 US: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 160
TABLE 87 US: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 161
TABLE 88 US: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 161
TABLE 89 US: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 161
TABLE 90 US: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION) 162
TABLE 91 CANADA: KEY MACROINDICATORS 163
TABLE 92 CANADA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 163
TABLE 93 CANADA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 163
TABLE 94 CANADA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 164
TABLE 95 CANADA: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 164
TABLE 96 CANADA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 164
TABLE 97 EUROPE: VETERINARY BIOLOGICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION 166
TABLE 98 EUROPE: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 166
TABLE 99 EUROPE: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 166
TABLE 100 EUROPE: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 167
TABLE 101 EUROPE: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 167
TABLE 102 EUROPE: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 167
TABLE 103 GERMANY: KEY MACROINDICATORS 168
TABLE 104 GERMANY: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 168
TABLE 105 GERMANY: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 169
TABLE 106 GERMANY: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 169
TABLE 107 GERMANY: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 169
TABLE 108 GERMANY: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 170
TABLE 109 UK: KEY MACROINDICATORS 171
TABLE 110 UK: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 171
TABLE 111 UK: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 171
TABLE 112 UK: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 172
TABLE 113 UK: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 172
TABLE 114 UK: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION) 172
TABLE 115 FRANCE: KEY MACROINDICATORS 173
TABLE 116 FRANCE: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 174
TABLE 117 FRANCE: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 174
TABLE 118 FRANCE: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 174
TABLE 119 FRANCE: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 175
TABLE 120 FRANCE: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 175
TABLE 121 ITALY: KEY MACROINDICATORS 176
TABLE 122 ITALY: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 176
TABLE 123 ITALY: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 176
TABLE 124 ITALY: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 177
TABLE 125 ITALY: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 177
TABLE 126 ITALY: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 177
TABLE 127 SPAIN: KEY MACROINDICATORS 178
TABLE 128 SPAIN: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 178
TABLE 129 SPAIN: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 179
TABLE 130 SPAIN: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 179
TABLE 131 SPAIN: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 179
TABLE 132 SPAIN: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 180
TABLE 133 NETHERLANDS: KEY MACROINDICATORS 180
TABLE 134 NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 181
TABLE 135 NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 181
TABLE 136 NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 181
TABLE 137 NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 182
TABLE 138 NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 182
TABLE 139 REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 183
TABLE 140 REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 183
TABLE 141 REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 183
TABLE 142 REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 184
TABLE 143 REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 184
TABLE 144 ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY COUNTRY
2023–2030 (USD MILLION 185
TABLE 145 ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 186
TABLE 146 ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 186
TABLE 147 ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 186
TABLE 148 ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 187
TABLE 149 ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 187
TABLE 150 JAPAN: KEY MACROINDICATORS 188
TABLE 151 JAPAN: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 188
TABLE 152 JAPAN: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 189
TABLE 153 JAPAN: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 189
TABLE 154 JAPAN: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 189
TABLE 155 JAPAN: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 190
TABLE 156 CHINA: KEY MACROINDICATORS 191
TABLE 157 CHINA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 191
TABLE 158 CHINA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 191
TABLE 159 CHINA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 192
TABLE 160 CHINA: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 192
TABLE 161 CHINA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 192
TABLE 162 INDIA: PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2000 VS. 2030 (THOUSAND METRIC TONS) 194
TABLE 163 INDIA: KEY MACROINDICATORS 194
TABLE 164 INDIA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 194
TABLE 165 INDIA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 195
TABLE 166 INDIA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 195
TABLE 167 INDIA: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 195
TABLE 168 INDIA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 196
TABLE 169 AUSTRALIA: KEY MACROINDICATORS 196
TABLE 170 AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 197
TABLE 171 AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 197
TABLE 172 AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 197
TABLE 173 AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 198
TABLE 174 AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 198
TABLE 175 SOUTH KOREA: KEY MACROINDICATORS 199
TABLE 176 SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 199
TABLE 177 SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 199
TABLE 178 SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 200
TABLE 179 SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 200
TABLE 180 SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 201
TABLE 181 NEW ZEALAND: KEY MACROINDICATORS 201
TABLE 182 NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 202
TABLE 183 NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 202
TABLE 184 NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 202
TABLE 185 NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 203
TABLE 186 NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 203
TABLE 187 REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 204
TABLE 188 REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 204
TABLE 189 REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 204
TABLE 190 REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 205
TABLE 191 REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 205
TABLE 192 LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION 206
TABLE 193 LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 206
TABLE 194 LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 207
TABLE 195 LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 207
TABLE 196 LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 208
TABLE 197 LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 208
TABLE 198 BRAZIL: KEY MACROINDICATORS 209
TABLE 199 BRAZIL: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 209
TABLE 200 BRAZIL: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 209
TABLE 201 BRAZIL: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 210
TABLE 202 BRAZIL: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 210
TABLE 203 BRAZIL: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 210
TABLE 204 MEXICO: KEY MACROINDICATORS 211
TABLE 205 MEXICO: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 211
TABLE 206 MEXICO: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 212
TABLE 207 MEXICO: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 212
TABLE 208 MEXICO: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 212
TABLE 209 MEXICO: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 213
TABLE 210 REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 213
TABLE 211 REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 214
TABLE 212 REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 214
TABLE 213 REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 214
TABLE 214 REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 215
TABLE 215 MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY REGION,
2023–2030 (USD MILLION) 216
TABLE 216 MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 216
TABLE 217 MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 216
TABLE 218 MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 217
TABLE 219 MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 217
TABLE 220 MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 218
TABLE 221 GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 218
TABLE 222 GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 219
TABLE 223 GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 219
TABLE 224 GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 219
TABLE 225 GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 220
TABLE 226 GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY END USER,
2023–2030 (USD MILLION) 220
TABLE 227 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS 221
TABLE 228 KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD MILLION) 221
TABLE 229 KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET,
BY ANIMAL TYPE, 2023–2030 (USD MILLION) 221
TABLE 230 KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 222
TABLE 231 KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 222
TABLE 232 KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 223
TABLE 233 UNITED ARAB EMIRATES (UAE): KEY MACROINDICATORS 223
TABLE 234 UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD MILLION) 224
TABLE 235 UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 224
TABLE 236 UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 224
TABLE 237 UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 225
TABLE 238 UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 225
TABLE 239 REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 226
TABLE 240 REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 226
TABLE 241 REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 226
TABLE 242 REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 227
TABLE 243 REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION) 227
TABLE 244 REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET,
BY PRODUCT TYPE, 2023–2030 (USD MILLION) 228
TABLE 245 REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET,
BY ANIMAL TYPE, 2023–2030 (USD MILLION) 228
TABLE 246 REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 228
TABLE 247 REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 229
TABLE 248 REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 229
TABLE 249 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN VETERINARY BIOLOGICS MARKET 230
TABLE 250 VETERINARY BIOLOGICS MARKET: DEGREE OF COMPETITION, 2024 233
TABLE 251 VETERINARY BIOLOGICS MARKET: DEGREE OF COMPETITION, 2024 234
TABLE 252 VETERINARY DIAGNOSTIC KITS MARKET: DEGREE OF COMPETITION, 2024 237
TABLE 254 VETERINARY BIOLOGICS MARKET: REGION FOOTPRINT 242
TABLE 255 VETERINARY BIOLOGICS MARKET: PRODUCT TYPE FOOTPRINT 243
TABLE 256 VETERINARY BIOLOGICS MARKET: ANIMAL TYPE FOOTPRINT 244
TABLE 257 VETERINARY BIOLOGICS MARKET: APPLICATION FOOTPRINT 245
TABLE 258 VETERINARY BIOLOGICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 248
TABLE 259 VETERINARY BIOLOGICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY ANIMAL TYPE AND REGION 249
TABLE 260 VETERINARY BIOLOGICS MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–AUGUST 2025 252
TABLE 261 VETERINARY BIOLOGICS MARKET: DEALS, JANUARY 2022–AUGUST 2025 253
TABLE 262 VETERINARY BIOLOGICS MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025 254
TABLE 263 VETERINARY BIOLOGICS MARKET: OTHER DEVELOPMENTS,
JANUARY 2022–AUGUST 2025 255
TABLE 264 ZOETIS SERVICES LLC: COMPANY OVERVIEW 256
TABLE 265 ZOETIS SERVICES LLC: PRODUCTS OFFERED 257
TABLE 266 ZOETIS SERVICES LLC: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–AUGUST 2025 259
TABLE 267 ZOETIS SERVICES LLC: DEALS, JANUARY 2022–AUGUST 2025 260
TABLE 268 ZOETIS SERVICES LLC: EXPANSIONS, JANUARY 2022–AUGUST 2025 260
TABLE 269 ZOETIS SERVICES LLC: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 261
TABLE 270 IDEXX: COMPANY OVERVIEW 262
TABLE 271 IDEXX: PRODUCTS OFFERED 263
TABLE 272 IDEXX: PRODUCT LAUNCHES, JANUARY 2022–AUGUST 2025 267
TABLE 273 ELANCO: COMPANY OVERVIEW 269
TABLE 274 ELANCO: PRODUCTS OFFERED 270
TABLE 275 ELANCO: PRODUCT LAUNCHES, JANUARY 2022–AUGUST 2025 271
TABLE 276 ELANCO: DEALS, JANUARY 2022–AUGUST 2025 271
TABLE 277 ELANCO: EXPANSIONS, JANUARY 2022−AUGUST 2025 272
TABLE 278 MERCK & CO., INC.: COMPANY OVERVIEW 273
TABLE 279 MERCK & CO., INC.: PRODUCTS OFFERED 274
TABLE 280 MERCK & CO., INC.: PRODUCT LAUNCHES, JANUARY 2022−AUGUST 2025 275
TABLE 281 MERCK & CO., INC.: EXPANSIONS, JANUARY 2022−AUGUST 2025 275
TABLE 282 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 277
TABLE 283 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 278
TABLE 284 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 280
TABLE 285 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED 281
TABLE 286 BOEHRINGER INGELHEIM INTERNATIONAL GMBH:
DEALS, JANUARY 2022–AUGUST 2025 282
TABLE 287 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS,
JANUARY 2022–AUGUST 2025 282
TABLE 288 NEOGEN CORPORATION: COMPANY OVERVIEW 283
TABLE 289 NEOGEN CORPORATION: PRODUCTS OFFERED 284
TABLE 290 NEOGEN CORPORATION: DEALS, JANUARY 2022–AUGUST 2025 285
TABLE 291 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 286
TABLE 292 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 287
TABLE 293 IMMUCELL CORPORATION: COMPANY OVERVIEW 288
TABLE 294 IMMUCELL CORPORATION: PRODUCTS OFFERED 289
TABLE 295 IMMUCELL CORPORATION: OTHER DEVELOPMENTS,
JANUARY 2022–AUGUST 2025 290
TABLE 296 INNOVATIVE DIAGNOSTICS: COMPANY OVERVIEW 291
TABLE 297 INNOVATIVE DIAGNOSTICS: PRODUCTS OFFERED 291
TABLE 298 BIONOTE USA INC.: COMPANY OVERVIEW 295
TABLE 299 BIOCHECK: COMPANY OVERVIEW 296
TABLE 300 PLASVACC USA: COMPANY OVERVIEW 297
TABLE 301 NOVAVIVE INC.: COMPANY OVERVIEW 298
TABLE 302 MG BIOLOGICS: COMPANY OVERVIEW 299
TABLE 303 STALLERGENES GREER: COMPANY OVERVIEW 300
TABLE 304 BIOSTONE ANIMAL HEALTH: COMPANY OVERVIEW 301
TABLE 305 COLORADO SERUM COMPANY: COMPANY OVERVIEW 302
TABLE 306 PADULA SERUMS PTY LTD.: COMPANY OVERVIEW 303
TABLE 307 LAKE IMMUNOGENICS: COMPANY OVERVIEW 304
TABLE 308 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW 304
TABLE 309 PRINCETON BIOMEDITECH CORPORATION: COMPANY OVERVIEW 305
TABLE 310 TETRACORE, INC.: COMPANY OVERVIEW 306
TABLE 311 VMRD, INC.: COMPANY OVERVIEW 307
TABLE 312 ANIMAB: COMPANY OVERVIEW 308
LIST OF FIGURES
FIGURE 1 VETERINARY BIOLOGICS MARKET SEGMENTATION & REGIONAL SCOPE 30
FIGURE 2 VETERINARY BIOLOGICS MARKET: YEARS CONSIDERED 32
FIGURE 3 VETERINARY BIOLOGICS MARKET: RESEARCH DESIGN 33
FIGURE 4 VETERINARY BIOLOGICS MARKET: KEY DATA FROM SECONDARY SOURCES 35
FIGURE 5 VETERINARY BIOLOGICS MARKET: KEY PRIMARY SOURCES 36
FIGURE 6 VETERINARY BIOLOGICS MARKET: INSIGHTS FROM KEY PRIMARIES 37
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 37
FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 38
FIGURE 9 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 38
FIGURE 10 VETERINARY BIOLOGICS MARKET SIZE ESTIMATION:
SUPPLY-SIDE ANALYSIS (2024) 39
FIGURE 11 VETERINARY BIOLOGICS MARKET SIZE ESTIMATION 40
FIGURE 12 VETERINARY BIOLOGICS MARKET: TOP-DOWN APPROACH 41
FIGURE 13 VETERINARY BIOLOGICS MARKET: BOTTOM-UP APPROACH 42
FIGURE 14 VETERINARY BIOLOGICS MARKET: CAGR PROJECTIONS 43
FIGURE 15 VETERINARY BIOLOGICS MARKET: DATA TRIANGULATION METHODOLOGY 44
FIGURE 16 VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE,
2025 VS. 2030 (USD MILLION) 47
FIGURE 17 VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE,
2025 VS. 2030 (USD MILLION) 48
FIGURE 18 VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION,
2025 VS. 2030 (USD MILLION) 48
FIGURE 19 VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 49
FIGURE 20 VETERINARY BIOLOGICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 50
FIGURE 21 GEOGRAPHICAL SNAPSHOT OF VETERINARY BIOLOGICS MARKET 51
FIGURE 22 INCREASING PREVALENCE OF CHRONIC DISEASES AMONG COMPANION ANIMALS TO DRIVE MARKET 52
FIGURE 23 US AND COMPANION ANIMALS COMMANDED LARGEST NORTH AMERICAN VETERINARY BIOLOGICS MARKET SHARE IN 2024 53
FIGURE 24 MONOCLONAL ANTIBODIES CAPTURED LARGEST SHARE DURING FORECAST PERIOD 53
FIGURE 25 COMPANION ANIMALS TO ACCOUNT FOR LARGEST MARKET SHARE IN 2030 54
FIGURE 26 INJECTABLE ROUTE OF ADMINISTRATION TO DOMINATE MARKET IN 2030 54
FIGURE 27 DERMATOLOGY TO LEAD VETERINARY BIOLOGICS MARKET IN 2030 55
FIGURE 28 US TO REGISTER HIGHEST GROWTH IN VETERINARY BIOLOGICS MARKET
FROM 2025 TO 2030 56
FIGURE 29 VETERINARY BIOLOGICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 57
FIGURE 30 VETERINARY BIOLOGICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 70
FIGURE 31 VETERINARY BIOLOGICS MARKET: VALUE CHAIN ANALYSIS 71
FIGURE 32 VETERINARY BIOLOGICS MARKET: PORTER’S FIVE FORCES ANALYSIS 73
FIGURE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER 75
FIGURE 34 KEY BUYING CRITERIA FOR MAJOR END USERS 76
FIGURE 35 PATENT ANALYSIS FOR VETERINARY MONOCLONAL ANTIBODIES IN VETERINARY BIOLOGICS MARKET, JANUARY 2014–AUGUST 2025 82
FIGURE 36 TOP APPLICANT COUNTRIES AND NUMBER OF PATENT APPLICANTS FOR VETERINARY MONOCLONAL ANTIBODIES, BY JURISDICTION,
JANUARY 2014–AUGUST 2025 83
FIGURE 37 VETERINARY BIOLOGICS MARKET: ECOSYSTEM ANALYSIS 87
FIGURE 38 KEY AI USE CASES IN VETERINARY BIOLOGICS MARKET 91
FIGURE 39 FUNDING AND NUMBER OF DEALS IN VETERINARY BIOLOGICS MARKET,
2020–2024 (USD MILLION) 92
FIGURE 40 NORTH AMERICA: VETERINARY BIOLOGICS MARKET SNAPSHOT 157
FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN VETERINARY BIOLOGICS
MARKET, 2022–2024 232
FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY BIOLOGICS
MARKET (2024) 232
FIGURE 43 US MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY BIOLOGICS MARKET (2024) 233
FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY DIAGNOSTIC KITS MARKET (2024) 236
FIGURE 45 US: VETERINARY DIAGNOSTIC KITS MARKET SHARE ANALYSIS, 2024 236
FIGURE 46 RANKING OF KEY PLAYERS IN VETERINARY BIOLOGICS MARKET (2024) 238
FIGURE 47 RANKING OF KEY PLAYERS IN VETERINARY DIAGNOSTIC KITS MARKET (2024) 239
FIGURE 48 VETERINARY BIOLOGICS MARKET: COMPANY EVALUATION MATRIX, 2024 240
FIGURE 49 VETERINARY BIOLOGICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 247
FIGURE 50 VETERINARY BIOLOGICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 250
FIGURE 51 EV/EBITDA OF KEY VENDORS 251
FIGURE 52 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 251
FIGURE 53 ZOETIS SERVICES LLC: COMPANY SNAPSHOT 257
FIGURE 54 IDEXX: COMPANY SNAPSHOT 263
FIGURE 55 ELANCO: COMPANY SNAPSHOT 270
FIGURE 56 MERCK & CO., INC.: COMPANY SNAPSHOT 274
FIGURE 57 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 278
FIGURE 58 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT 281
FIGURE 59 NEOGEN CORPORATION: COMPANY SNAPSHOT 284
FIGURE 60 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 287
FIGURE 61 IMMUCELL CORPORATION: COMPANY SNAPSHOT 289
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11